In vitro activity of xanthorrhizol against Candida glabrata, C. guilliermondii, and C. parapsilosis biofilms

Medical Mycology

Volumn 49, Issue 1, 2010, Pages 1-9

  Rukayadi, Yaya ^a,b   Han, Sunghwa ^a   Yong, Dongeun ^a   Hwang, Jae Kwan ^a  

^a Yonsei University   (South Korea)

^b BOGOR AGRICULTURAL UNIVERSITY   (Indonesia)

Author keywords

amphotericin B; biofilms; non Candida albicans Candida (NCAC); Xanthorrhizol

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CURCUMA XANTHORRHIZA EXTRACT; PLANT EXTRACT; UNCLASSIFIED DRUG; XANTHORRHIZOL;

ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ARTICLE; BIOFILM; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CELL DENSITY; CELL VIABILITY; DRUG POTENCY; FUNGUS GROWTH; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PICHIA GUILLIERMONDII; PLANKTON; XANTHORRHIZA;

ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; HUMANS; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; OXIDATION-REDUCTION; PHENOLS; STAINING AND LABELING; TETRAZOLIUM SALTS;

CANDIDA; CANDIDA ALBICANS; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS;

EID: 78650363934     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693786.2010.492482     Document Type: Article

References (40)

1. Jarvis WR. Epidemiology of nosocomial fungal infections, with emphasis on Candida species. Clin Infect Dis 1995; 20: 1526-1530.
2. Jabra-Rizk MA, Falkler WA, Meiller TF. Fungal biofi lms and drug resistance. Emerg Infect Dis 2004; 10: 14-19.
3. Klepser ME. C andida resistance and its clinical relevance. P harmacotherapy 2006; 26: 68S - 75S.
4. Kwon Chung KJ, Bennett JE. Candidiasis. In: Kwon Chung KJ, Bennett JE (eds), Medical Mycology . Philadelphia, PA: Lea and Febiger, 1992; 280-336.
5. Ng KP, Madasamy M, Saw TL, et al. C andida biotypes isolated from clinical specimens in Malaysia. Mycopathologia 1999; 144: 135-140.
6. Panizo MM, Revi á kina V, Dolande M, Selgrad S. C andida spp. in vitro susceptibility profi le to four antifungal agents. Resistance surveillance study in Venezuelan strains. Med Mycol 2009; 47: 137-143.
7. Weems JJ Jr, Chamberland ME, Ward J, et al. Candida parapsilosis fungemia associated with parenteral nutrition and contaminated blood pressure transducers. J Clin Microbiol 1987; 25: 1029-1032.
8. Khun DM, Chandra J, Mukherjee PK, Ghannoum MA. Comparison of biofi lm formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 2002; 70: 878-888.
9. Douglas LJ. C andida biofi lms and their role in infection. T rends Microbiol 2003; 11: 30-36.
10. Ramage G, Mart í nez JP, L ópez-Ribot JL. C andida biofi lms on implanted biomaterials: a clinical signifi cant problem. FEMS Yeast Res 2006; 6: 979-986.
11. Ficker CE, Smith ML, Susiarti S, et al. Inhibition of human pathogenic fungi by members of Zingiberaceae used by the Kenyah (Indonesian Borneo). J Ethnopharmacol 2003; 85: 289-293.
12. Rocha AD, de Oliveira AB, de Souza Filho JD , Lombardi JA, Braga FC. Antifungal constituents of Clytostoma ramentaceum and Mansoa hirsuta . Phytother Res 2004; 18: 463-467.
13. Arras G, Usai M. Fungitoxic activity of 12 essential oils against four postharvest citrus pathogens: chemical analysis of Thymus capitatus oil and its effect in subatmospheric pressure conditions. J Food Prot 2001; 64: 1025-1029.
14. Chami N, Chami F, Bennis S, Trouillas J, Remmal A. Antifungal treatment with carvacrol and eugenol of oral candidiasis in immunosuppressed rats. Braz J Infect Dis 2004; 8: 217-226.
15. Hwang JK, Shim JS, Pyun YR. Antibacterial activity of xanthorrhizol from Curcuma xanthorrhiza against oral pathogens. Fitoterapia 2000; 71: 321-323.
16. Hwang JK, Shim JS, Baek NI, Pyun YR. Xanthorrhizol: a potential antibacterial agent from Curcuma xanthorrhiza against Streptococcus mutans . Planta Med 2000; 66: 196-197.
17. Kim SH, Hong KO, Chung WY, Hwang JK, Park KK. Abrogation of cisplatin-induced hepatotoxicity in mice by xanthorrhizol is related to its effect on the regulation of gene transcription. Toxicol Appl Pharmacol 2004; 196: 346-355.
18. Lim CS, Jin DQ, Mok H, et al. Antioxidant and antiinfl ammatory activities of xanthorrhizol in hippocampal neurons and primary cultured microglia. J Neurosci Res 2005; 82: 831-838.
19. Rukayadi Y, Lee K, Lee M, Yong D, Hwang JK. Synergistic anticandidal activity of xanthorrhizol in combination with ketoconazole or amphotericin B. FEMS Yeast Res 2009; 9: 1302-1311.
20. Rukayadi Y, Yong D, Hwang JK. I n vitro anticandidal activity of xanthorrhizol isolated from Curcuma xanthorrhiza Roxb. J Antimicrob Chemother 2006; 57: 1231-1234.
21. Rukayadi Y, Hwang JK. I n vitro anti-M alassezia activity of xanthorrhizol isolated from Curcuma xanthorrhiza Roxb. Lett Appl Microbiol 2007 ; 44: 126-130.
22. Rukayadi Y, Hwang JK. In vitro antimycotic activity of xanthorrhizol isolated from Curcuma xanthorrhiza Roxb. against opportunistic fi lamentous fungi. Phytother Res 2007; 21: 434-438.
23. Rukayadi Y, Hwang JK. In vitro activity of xanthorrhizol against S treptococcus mutans biofi lms. Lett Appl Microbiol 2006; 42: 400-404.
24. Rukayadi Y, Hwang JK. Effect of coating the wells of a polystyrene microtiter plate with xanthorrhizol on the biofi lm formation of Streptococcus mutans . J Basic Microbiol 2006; 46: 410-415.
25. Yanti, Rukayadi Y, Lee K, et al. Anti-biofi lm activity of xanthorrhizol isolated from Curcuma xanthorrhiza Roxb. against bacterial biofi lms formed by saliva and artifi cial multi-species oral strains. Food Sci Biotechnol 2009; 18: 556-560.
26. Pierce CG, Uppuluri P, Tristan AR, et al. A simple and reproducible 96-well plate-based method for the formation of fungal biofi lms and its application to antifungal susceptibility testing. Nat Protoc 2008; 3: 1494-1500.
27. Clinical and Laboratory Standards Institute. R eference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast-Second Edition: Approved Standard M27-A2. CLSI, Wayne, PA, USA, 2002.
28. Bachmann SP, VandeWalle K, Ramage G, et al. In vitro activity of caspofungin against Candida albicans biofi lms. Antimicrob Agents Chemother 2002; 46: 3591-3596.
29. Chandra J, Mukherjee PK, Ghannoum MA. In vitro growth and analysis of Candida biofi lms. Nat Protoc 2008; 3: 1909-1924.
30. Hawser SP, Norris H, Jessup CJ, Gannoum MA. Comparison of a 2,3- bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]- 2H-tetrazolium hydroxide (XTT)) colorimetric method with the standardized National Committee for Clinical Laboratory Standards method of testing clinical yeast isolates for susceptibility to antifungal agents. J Clin Microbiol 1998; 36: 1450-1452.
31. Tortorano AM, Prigitano A, Biraghi E, Viviani MA, FIMUA-ECMM Candidaemia Study Group. The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: in vitro susceptibility of 375 Candida albicans isolates and biofi lm production. J Antimicrob Chemother 2005; 56: 777-779.
32. Linos A, Berekaa MM, Reichelt R, et al. Biodegradation of c is -1 ,4-polyisoprene rubbers by distinct actinomycetes: microbial strategies and detail surface analysis. Appl Environ Microbiol 2000; 66: 1639-1645.
33. Mukherjee PK, Chandra J. C andida biofi lm resistance. D rug Resist Updat 2004; 7: 301-309.
34. Shin S, Pyun MS . Anti-Candida effects of estragole in combination with ketoconazole or amphotericin B . Phytother Res 2004; 18: 827-830.
35. Chami N, Bennis S, Chami F, Aboussekhra A, Remmal A. Study of anticandidal activity of carvacrol and eugenol in vitro and in vivo . Oral Microbiol Immunol 2005; 20: 106-111.
36. Agarwal V, Lal P, Pruthi V. Prevention of Candida albicans biofilm by plant oils. Mycopathologia 2008; 165: 13-19.
37. He M, Du M, Fan M, Bian Z. I n vitro activity of eugenol against Candida albicans biofi lms. Mycopathologia 2007; 163: 137-143.
38. Helmerhorst EJ, Reijnders IM, van t Hof W, et al. Amphotericin Band fl uconazole-resistant Candida spp., Aspergillus fumigatus , and other newly emerging pathogenic fungi are susceptible to basic antifungal peptides. Antimicrob Agents Chemother 1999; 43: 702-704.
39. Wakabayashi H, Abe S, Teraguchi S, Hayasawa H, Yamaguchi H. Inhibition of hyphal growth of azole-resistant strains of Candida albicans by triazole antifungal agents in the presence of lactoferrin-related compounds. Antimicrob Agents Chemother 1998; 42: 1587-1591.
40. Cohen BE. Amphotericin B toxicity and lethality: a tale of two channels. Int J Pharm 1998; 162: 95-106.